Therefore, our analysis reveals that the expression of BTN2A1/BTN3A1 is low on the tumor cells in mesothelioma, where a high percentage of cells express PD-L1/PD-L2, which could hinder the effectiveness of Vδ2 T cells for immunotherapy. The gene discussed is BTN3A1; the disease is mesothelioma.